• Something wrong with this record ?

Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality

K. Smetana, D. Rosel, J. Brábek,

. 2020 ; 34 (5) : 3027-3028. [pub] -

Language English Country Greece

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc20024804

The FDA-approved drugs raloxifene and bazedoxifene could be among the best candidates to prevent mortality in severe COVID-19 patients. Raloxifene and bazedoxifene inhibit IL-6 signaling at therapeutic doses, suggesting they have the potential to prevent the cytokine storm, ARDS and mortality in severe COVID-19 patients, as is being shown with humanized antibodies blocking IL-6 signaling. In addition, raloxifene and bazedoxifene are selective estrogen receptor modulators with strong antiviral activity.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20024804
003      
CZ-PrNML
005      
20220119145207.0
007      
ta
008      
201125s2020 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/invivo.12135 $2 doi
035    __
$a (PubMed)32871847
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Smetana, Karel $u Institute of Anatomy, First Faculty of Medicine, Charles University, Prague, Czech Republic jan.brabek@natur.cuni.cz karel.smetana@lf1.cuni.cz. BIOCEV, Vestec, Czech Republic.
245    10
$a Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality / $c K. Smetana, D. Rosel, J. Brábek,
520    9_
$a The FDA-approved drugs raloxifene and bazedoxifene could be among the best candidates to prevent mortality in severe COVID-19 patients. Raloxifene and bazedoxifene inhibit IL-6 signaling at therapeutic doses, suggesting they have the potential to prevent the cytokine storm, ARDS and mortality in severe COVID-19 patients, as is being shown with humanized antibodies blocking IL-6 signaling. In addition, raloxifene and bazedoxifene are selective estrogen receptor modulators with strong antiviral activity.
650    _2
$a Betacoronavirus $x účinky léků $x patogenita $7 D000073640
650    _2
$a koronavirové infekce $x farmakoterapie $x genetika $x mortalita $x virologie $7 D018352
650    _2
$a cytokiny $x antagonisté a inhibitory $x genetika $7 D016207
650    _2
$a lidé $7 D006801
650    _2
$a indoly $x farmakologie $7 D007211
650    _2
$a interleukin-6 $x antagonisté a inhibitory $x genetika $7 D015850
650    _2
$a pandemie $7 D058873
650    _2
$a virová pneumonie $x farmakoterapie $x genetika $x mortalita $x virologie $7 D011024
650    _2
$a raloxifen hydrochlorid $x farmakologie $7 D020849
650    _2
$a receptory pro estrogeny $x antagonisté a inhibitory $7 D011960
650    _2
$a syndrom dechové tísně $x farmakoterapie $x prevence a kontrola $x virologie $7 D012128
650    _2
$a selektivní modulátory estrogenních receptorů $x farmakologie $7 D020845
650    _2
$a signální transdukce $x účinky léků $7 D015398
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rosel, Daniel $u BIOCEV, Vestec, Czech Republic. Department of Cell Biology, Faculty of Sciences, Charles University, Prague, Czech Republic.
700    1_
$a Brábek, Jan, $u BIOCEV, Vestec, Czech Republic jan.brabek@natur.cuni.cz karel.smetana@lf1.cuni.cz. Department of Cell Biology, Faculty of Sciences, Charles University, Prague, Czech Republic. $d 1973- $7 xx0268678
773    0_
$w MED00175831 $t In vivo (Athens, Greece) $x 1791-7549 $g Roč. 34, č. 5 (2020), s. 3027-3028
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32871847 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20220119145203 $b ABA008
999    __
$a ok $b bmc $g 1598949 $s 1115490
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 34 $c 5 $d 3027-3028 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options